Last reviewed · How we verify
Halocur (HALOFUGINONE)
Halocur (generic name: HALOFUGINONE) is a drug. It is currently FDA-approved.
Halofuginone (Halocur) is a marketed small molecule that modulates cellular pathways to produce a therapeutic effect, though its primary indication and revenue figures are unspecified. A key strength of Halocur is its patent protection, which extends until 2028, providing a period of exclusivity in its market segment. The primary risk facing Halocur is the lack of detailed clinical trial results and competitor information, which may impact its market position and strategic planning.
At a glance
| Generic name | HALOFUGINONE |
|---|---|
| Target | Proline--tRNA ligase, PfPRS, EC 6.1.1.15 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open Label Extension Study of HT-100 in Patients With DMD (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy (PHASE1,PHASE2)
- HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02 (PHASE2)
- Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma (PHASE2)
- Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halocur CI brief — competitive landscape report
- Halocur updates RSS · CI watch RSS
Frequently asked questions about Halocur
What is Halocur?
What is the generic name of Halocur?
What development phase is Halocur in?
What does Halocur target?
Related
- Target: All drugs targeting Proline--tRNA ligase, PfPRS, EC 6.1.1.15
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing